{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T14:00:26Z","timestamp":1784815226424,"version":"3.55.0"},"reference-count":33,"publisher":"Georg Thieme Verlag KG","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Perinatol"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:p>\n            Objective\u2003This study aimed to determine whether infants who were treated with intravitreal bevacizumab (IVB) for retinopathy of prematurity (ROP) were at higher risk of death or neurodevelopmental impairment (NDI) when compared with infants who were not treated with IVB (Laser only).<\/jats:p><jats:p>\n            Study Design\u2003This retrospective study included 146 infants born from 2009 through 2016 with a birth weight (BW) &lt;1,000\u2009g, gestational age &lt;27 weeks, and required ROP therapy. Death and NDI rates were assessed at 18 to 24 months' corrected age.<\/jats:p><jats:p>\n            Results\u2003Rates of death or severe NDI were 62 and 53% in the IVB (n\u2009=\u200961) and Laser only (n\u2009=\u200985) groups, respectively. This difference was not statistically different despite sample selection bias in treating growth-restricted infants with IVB, BW (median [IQR]) was 481 (420\u2013583) versus 547 (473\u2013640) g in IVB and Laser only groups, respectively, p\u2009=\u20090.003. The adjusted odds ratio and 95% confidence interval of death or severe NDI was 0.86 (0.33\u20132.20).<\/jats:p><jats:p>\n            Conclusion\u2003Bevacizumab therapy for ROP did not affect survival and neurodevelopment of extremely preterm infants.<\/jats:p><jats:p>\n            Key Points\n          <\/jats:p>","DOI":"10.1055\/s-0040-1710556","type":"journal-article","created":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T22:31:01Z","timestamp":1590273061000},"page":"1158-1166","source":"Crossref","is-referenced-by-count":17,"title":["Bevacizumab for Retinopathy of Prematurity: 2-Year Neurodevelopmental Follow-up"],"prefix":"10.1055","volume":"38","author":[{"given":"Michael","family":"Zayek","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Department of Pediatrics, University of South Alabama, Mobile, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn","family":"Parker","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Department of Pediatrics, University of South Alabama, Mobile, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Rydzewska","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Neonatal Medicine, Crozer-Keystone Health System, Upland, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aref","family":"Rifai","sequence":"additional","affiliation":[{"name":"Retina Center of Pensacola, Pensacola, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramachandra","family":"Bhat","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Department of Pediatrics, University of South Alabama, Mobile, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Eyal","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Department of Pediatrics, University of South Alabama, Mobile, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2020,5,23]]},"reference":[{"issue":"12","key":"ref1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.earlhumdev.2012.09.019","article-title":"Treatment of retinopathy of prematurity with vascular endothelial growth factor inhibitors","volume":"88","author":"H A Mintz-Hittner","year":"2012","journal-title":"Early Hum Dev"},{"issue":"04","key":"ref2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archopht.1988.01060130517027","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results","volume":"106","year":"1988","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"ref3","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ajo.2006.02.018","article-title":"Retinopathy of prematurity: two distinct mechanisms that underlie zone 1 and zone 2 disease","volume":"142","author":"J T Flynn","year":"2006","journal-title":"Am J Ophthalmol"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1046\/j.1442-9071.2000.00226.x","article-title":"Vitreal macrophages express vascular endothelial growth factor in oxygen-induced retinopathy","volume":"28","author":"H L Naug","year":"2000","journal-title":"Clin Exp Ophthalmol"},{"issue":"07","key":"ref6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"H A Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"issue":"04","key":"ref7","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","article-title":"Serum vascular endothelialgrowth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity","volume":"37","author":"W-C Wu","year":"2017","journal-title":"Retina"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1523\/JNEUROSCI.4445-12.2013","article-title":"Neurogenesis continues in the third trimester of pregnancy and is suppressed by premature birth","volume":"33","author":"S Malik","year":"2013","journal-title":"J Neurosci"},{"issue":"11","key":"ref9","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.ophtha.2019.03.048","article-title":"Neurodevelopmental outcomes after intravitreal bevacizumab therapy for petinopathy of prematurity: a prospective case-control study","volume":"126","author":"Y Y Fan","year":"2019","journal-title":"Ophthalmology"},{"issue":"04","key":"ref10","doi-asserted-by":"crossref","first-page":"e20153218","DOI":"10.1542\/peds.2015-3218","article-title":"Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity","volume":"137","author":"J Morin","year":"2016","journal-title":"Pediatrics"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"e0148019","DOI":"10.1371\/journal.pone.0148019","article-title":"Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment","volume":"11","author":"R Lien","year":"2016","journal-title":"PLoS One"},{"issue":"02","key":"ref12","doi-asserted-by":"crossref","first-page":"e20183537","DOI":"10.1542\/peds.2018-3537","article-title":"Neurodevelopmental outcomes of preterm infants with retinopathy of prematurity by treatment","volume":"144","author":"G Natarajan","year":"2019","journal-title":"Pediatrics"},{"issue":"09","key":"ref13","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/s41372-019-0420-z","article-title":"Neurodevelopmental outcomes in infants treated with intravitreal bevacizumab versus laser","volume":"39","author":"K Raghuram","year":"2019","journal-title":"J Perinatol"},{"issue":"02","key":"ref14","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/archpediatrics.2010.285","article-title":"The limit of viability: a single regional unit's experience","volume":"165","author":"M M Zayek","year":"2011","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"02","key":"ref15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0029-7844(95)00386-X","article-title":"A United States national reference for fetal growth","volume":"87","author":"G R Alexander","year":"1996","journal-title":"Obstet Gynecol"},{"issue":"04","key":"ref17","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0022-3476(78)80282-0","article-title":"Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm","volume":"92","author":"L A Papile","year":"1978","journal-title":"J Pediatr"},{"key":"ref18","first-page":"8","article-title":"A report: the definition and classification of cerebral palsy April 2006","volume":"109","author":"P Rosenbaum","year":"2007","journal-title":"Dev Med Child Neurol Suppl"},{"issue":"16","key":"ref19","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa073059","article-title":"Intensive care for extreme prematurity--moving beyond gestational age","volume":"358","author":"J E Tyson","year":"2008","journal-title":"N Engl J Med"},{"key":"ref20","first-page":"112","volume-title":"Regression Models for Categorical Dependent Variables Using Stata, 2nd ed","author":"J S Scott","year":"2006"},{"issue":"01","key":"ref21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jaapos.2017.10.006","article-title":"Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity","volume":"22","author":"K A Kennedy","year":"2018","journal-title":"J AAPOS"},{"issue":"19","key":"ref22","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1410689","article-title":"Between-hospital variation in treatment and outcomes in extremely preterm infants","volume":"372","author":"M A Rysavy","year":"2015","journal-title":"N Engl J Med"},{"issue":"03","key":"ref23","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ajo.2015.05.016","article-title":"Inter-expert and intra-expert agreement on the diagnosis and treatment of retinopathy of prematurity","volume":"160","author":"A Gschlie\u00dfer","year":"2015","journal-title":"Am J Ophthalmol"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1164\/rccm.201409-1594OC","article-title":"Early pulmonary vascular disease in preterm infants at risk for bronchopulmonary dysplasia","volume":"191","author":"P M Mourani","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"07","key":"ref25","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/jp.2012.164","article-title":"Fetal growth restriction and pulmonary hypertension in premature infants with bronchopulmonary dysplasia","volume":"33","author":"J Check","year":"2013","journal-title":"J Perinatol"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1542\/peds.2008-0338","article-title":"Neurodevelopmental outcome of extremely low birth weight infants randomly assigned to restrictive or liberal hemoglobin thresholds for blood transfusion","volume":"123","author":"R K Whyte","year":"2009","journal-title":"Pediatrics"},{"issue":"11","key":"ref27","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial","volume":"132","author":"M M Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"ref28","first-page":"4565216","article-title":"Refractive and biometric outcomes in patients with retinopathy of prematurity treated with intravitreal injection of ranibizumab as compared with bevacizumab: a clinical study of correction at three years of age","volume":"2018","author":"Y C Chen","year":"2018","journal-title":"J Ophthalmol"},{"issue":"04","key":"ref29","doi-asserted-by":"crossref","first-page":"e475","DOI":"10.1111\/aos.13004","article-title":"Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison","volume":"96","author":"J Han","year":"2018","journal-title":"Acta Ophthalmol"},{"issue":"08","key":"ref30","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","article-title":"Reactivation of retinopathy of prematurity after bevacizumab injection","volume":"130","author":"J Hu","year":"2012","journal-title":"Arch Ophthalmol"},{"issue":"04","key":"ref31","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1001\/jamaophthalmol.2013.711","article-title":"Recurrence of retinopathy of prematurity following bevacizumab monotherapy: is it only the tip of the iceberg?","volume":"131","author":"K Mireskandari","year":"2013","journal-title":"JAMA Ophthalmol"},{"issue":"03","key":"ref32","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S0161-6420(94)31301-7","article-title":"Postnatal retinal vascularization in former preterm infants with retinopathy of prematurity","volume":"101","author":"H A Mintz-Hittner","year":"1994","journal-title":"Ophthalmology"},{"issue":"10","key":"ref33","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.ophtha.2016.06.055","article-title":"Chronic vascular arrest as a predictor of bevacizumab treatment failure in retinopathy of prematurity","volume":"123","author":"B C Toy","year":"2016","journal-title":"Ophthalmology"},{"issue":"06","key":"ref34","doi-asserted-by":"crossref","first-page":"e20183061","DOI":"10.1542\/peds.2018-3061","article-title":"Screening examination of premature infants for retinopathy of prematurity","volume":"142","author":"W M Fierson","year":"2018","journal-title":"Pediatrics"}],"container-title":["American Journal of Perinatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0040-1710556.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T22:47:21Z","timestamp":1629845241000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0040-1710556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,23]]},"references-count":33,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,8,24]]},"published-print":{"date-parts":[[2021,9]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0040-1710556","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0735-1631","1098-8785"],"issn-type":[{"value":"0735-1631","type":"print"},{"value":"1098-8785","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,23]]}}}